Indication-based pricing experiment by Express Scripts gets off to a quiet start; HHS makes progress on factoring Rx spending in its risk adjustment calculations for ACA plans and the National Pharmaceutical Council releases recommended standards for drug value assessments.
Pharmacy benefit manager Express Scripts Holding Co. launched its indication-based pricing pilot program for oncology drugs to clients in March, a company spokesman confirmed. However, the PBM is not currently disclosing which drugs may be covered by the program.
“Our clients are aware of the details regarding each associated oncology medication. For the time being, though, we are deferring...
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
